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Abstract 
Objective: Identifying and recruiting people with early pre‑symptomatic Alzheimer’s disease to neuroimaging 
research studies is increasingly important. The extent to which results of these studies can be generalised depends 
on the recruitment and representativeness of the participants involved. We now report the recruitment and participa‑
tion patterns from a neuroscience sub‑study of the MRC National Survey of Health and Development, “Insight 46”. This 
study aimed to recruit 500 participants for extensive clinical and neuropsychological testing, and neuroimaging. We 
investigate how sociodemographic factors, health conditions and health‑related behaviours predict participation at 
different levels of recruitment.
Results: We met our target recruitment (n = 502). Higher educational attainment and non‑manual socio‑economic 
position (SEP) were consistent predictors of recruitment. Health‑related variables were also predictive at every level 
of recruitment; in particular higher cognition, not smoking and better self‑rating health. Sex and APOE‑e4 status were 
not predictors of participation at any level. Whilst recruitment targets were met, individuals with lower SEP, lower 
cognition, and more health problems are under‑represented in Insight 46. Understanding the factors that influence 
recruitment are important when interpreting results; for Insight 46 it is likely that health‑related outcomes and life 
course risks will under‑estimate those seen in the general population.
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Introduction
There is growing interest in recruiting people with 
early pre-symptomatic Alzheimer’s disease (AD) into 
neuroimaging studies [1]. Successful recruitment of 
older adults into dementia studies  is notably challeng-
ing [2–4]; efforts are being made to create registers and 
“ready-made” cohorts, which includes embedding sub-
studies within existing longitudinal studies [5–7]. To 
plan relevant studies, and interpret whether results are 
generalisable, it is important to understand factors that 
influence recruitment and retention [8, 9]. For example, 
educational and socioeconomic disadvantage are well 
established factors of drop out in longitudinal popula-
tion-based studies [8–10].
The Medical Research Council National Survey of 
Health and Development (NSHD) is the longest run-
ning British birth cohort and has assessed individu-
als from birth [11]. At the 23rd follow-up at age 60–64, 
the cohort sample has remained broadly representative 
of the general population [8]. Over the first 69  years of 
follow-up, participation rates have varied between 78 and 
94% [11, 12], and have not declined with age, but those 
of lower SEP and cognition are less likely to participate 
[8, 11]. Here we provide an overview of recruitment and 
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participation in Insight 46, a detailed neuroscience sub-
study of NSHD.
Main text
Methods
Procedure
The NSHD is a representative sample of 5362 males and 
females who were born in England, Scotland and Wales 
in 1  week in March 1946. The 24th data collection was 
conducted at age 68–69  years [11]. Insight 46 has been 
described in detail elsewhere [7]. In brief, 502 partici-
pants attended a clinic in University College London 
where they took part in a whole day of testing. Partici-
pants underwent neuropsychological and neurological 
examination and 60-min scanning session, with simul-
taneous collection of dynamic β-amyloid PET (370 MBq 
florbetapir F18) and MRI. Ethical approval for Insight 
46 was granted by the National Research Ethics Service 
(NRES) Committee London (14/LO/1173).
Recruitment
The first stage of recruitment consisted of identifying 
NSHD participants who had not previously withdrawn, 
died, or remained untraced from the main study by age 
69 (Fig.  1, max n = 2698). Participants were asked if 
they were willing to take part in a smaller clinical trial 
(yes = 40%), and if so, travel if this clinic was in London 
(yes = 70%).
Participants were defined as eligible for recruitment 
to Insight 46 if they met the criteria of having a defined 
set of life course data available (outlined in Additional 
file 1: Table S3 [7]) (Fig. 1a); and expressed willingness 
to come to a London-based clinic visit (Fig.  1b). Invi-
tations were sent to 779 eligible participants (Fig.  1c). 
To reach our target sample of 500, towards the end 
of recruitment we relaxed for key life course data to 
include participants without a previous measure of lung 
function, smoking or physical exercise (n = 62). Invited 
participants were screened by telephone, and attended 
the research centre (n = 502, Fig. 1d). Participants were 
excluded if they had contraindications to MRI or PET, 
such as severe claustrophobia, or implantable devices 
such as pacemakers and intracranial clips [7]. Of the 
502 participants, 471 completed scanning (Fig. 1e).
Acve sample at age 
69
n = 2689
Available specific dataset
n = 1322
Willing to aend 
London-based clinic 
n = 779
Invited for study 
parcipaon
n = 841 
Aended research centre 
n =  502
Completed scan
n= 471
No scan 
N = 31
Did not aend research 
centre
n = 339
Unknown willingness
n = 302
Not willing to aend 
London-based clinic 
n = 241
Incomplete dataset
N = 1367
Refusals n=204
Temporary refusals n=28
Not eligible n=69
Non-response n=12
Deaths nofied n=3
Cancelled visits n=23
n=62
a Defined set of life course data 
available
b Willing for London-visit
c Invited*
d Aended
e Completed
Fig. 1 Deriving the sample for the neuroscience sub‑study of the MRC National Survey of Health and Development, Insight 46, at age 69–71. 
*Eligibility for recruitment was considered if participants met the criteria of having a specific set of life course data available (outlined in Additional 
file 1: Table S3) and previously indicated they may be willing to attend a London‑based clinic
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Predictors of participation
We investigated socioeconomic and health-related 
characteristics previously associated with participation 
[8, 11]. Childhood socioeconomic position (SEP) was 
derived from paternal occupation; adult SEP was derived 
from participants’ own occupation at 53 years. SEP was 
dichotomised into manual (skilled manual, semi-skilled 
and unskilled) or non-manual (professional, intermedi-
ate, skilled non-manual) professions. The highest educa-
tional attainment achieved by 26  years was categorised 
into: no qualification; vocational only, ordinary (‘O’) 
level or equivalent; and advanced (‘A’) level or equiva-
lent, or higher [13]. Childhood cognitive function was 
derived from four tests of verbal and non-verbal abil-
ity [14]. Adult verbal memory was captured by a word 
list learning test at age 69 [15]. Cognitive scores were 
grouped [8, 16] into lowest 10%, middle 80% and highest 
10%. APOE-e4 status derived from a blood sample at age 
53 [17] was categorised as no ε4; heterozygous ε4; and 
homozygous ε4. The remaining measures were obtained 
at ages 68–69. Affective symptoms were measured using 
the 28-item version of the General Health Questionnaire 
[18] and a validated threshold indicated severity con-
sistent with a “mental health disorder”. Lifetime smok-
ing years was recoded as: never, ex and current smoker. 
Alcohol use was recorded as: never, less than once a 
week, 2–3 times per week, or 4+ times per week. Based 
on measured height and weight, participants were classi-
fied as not overweight (body mass index (BMI) < 25.0 kg/
m2), overweight (BMI of 25.0 to < 30.0 kg/m2), or obese 
(BMI > 30.0  kg/m2). Type II diabetes was based on self-
report of doctor diagnosis or use of diabetic medication 
up to age 69. Hypertension was based on self-report of 
doctor diagnosis. Overall disease burden was previously 
derived [11]. Participants self-rated their health as poor, 
fair, good, very good or excellent.
To derive residence distance  from London we calcu-
lated the straight-line distance in miles between partici-
pants’ post codes recorded in 2016 to the postcode of our 
London-based Research Centre. Distance was catego-
rised as: < 60, 60–120, 120–180, or > 180 miles.
Analysis
We investigated how sociodemographic and health-
related characteristics differed in four stages of recruit-
ment and participation (Fig.  1): (1) between those with 
key life course data vs. those not; of those, (2) between 
those willing to attend the clinic vs. not; of those (3) 
between those who attended vs. those who did not; of 
those (4) between those who completed neuroimaging vs. 
those who did not. Multivariable logistic regression mod-
els estimated associations between predictors and the 
above stages. Models were initially unadjusted (Table 1), 
then adjusted for sex, education, childhood and adult 
SEP (Table 2). 
Results
Distributions of predictors at each level are shown in 
Additional file 1: Table S1.
Those with key life course data
Of 2689 participants initially identified, 1322 (50%) had 
key life course data and previously attended a clinic 
(Fig.  1a). Eligibility was associated with non-manual 
childhood and adult SEP and higher education (Table 1) 
not with sex. Those eligible had higher cognitive perfor-
mance, alcohol intake and self-rated health; and lower 
lifetime smoking, and fewer mental and other health 
problems. Adjustment for sex, education and SEP slightly 
attenuated some of these results (Table 2). Although the 
bigger predictor was being in the highest 10% of child-
hood cognitive scores (OR = 3.23 (95% CI 2.19, 4.75)), 
this was attenuated substantially by adjustment for other 
early factors (OR = 1.06 (0.68, 1.65) Table  2). There was 
no difference in eligibility by APOE-e4 status.
Those willing to attend a London‑based assessment
Of the above 1322 eligible, 779 (59%) indicated willing-
ness to attend a London clinic, 302 (23%) did not indi-
cate a preference, and 241 (18%) declined (Fig.  1b). As 
with eligibility, non-manual SEP and higher education, 
but not gender, were associated with higher likelihood of 
this willingness. Higher cognitive performance and non-
smoking were predictors of willingness, although these 
differences were largely attenuated after adjustment for 
early factors (Table 2). While there was limited evidence 
for differences in mental health, health and health-related 
behaviours and APOE-e4 status between those willing 
and not willing to attend, those who rated their health 
as “excellent” were more likely to be willing (OR = 2.98 
(1.31, 6.79)). Having a residential address the furthest 
away from the research centre was associated with lower 
willingness (OR = 0.38 (0.27, 0.52)).
Those invited into the study
All the above 779 were invited (Fig.  1c). When recruit-
ment was underway the life course data criterion was 
relaxed to include 62 participants without a previous 
measure of lung function, smoking or physical exercise.
Those who attended the research centre
Of the 841 invited, 502 (60%) attended the clinic; 204 
(24%) refused, 28 (3%) temporarily refused, 12 (1%) did 
not respond, 3 (0.4%) died, 23 (3%) cancelled visits and 69 
(8%) were excluded (Fig. 1d) for reasons including severe 
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Table 2 Socioeconomic and  health characteristics predictors of  levels of  recruitment for  Insight 46, adjusting for  sex, 
childhood and adult SEP and education
Variable A. Specific life course data 
available
B. Willingness for London-
clinic
C. Attended D. Scanned
OR P 95% CI OR P 95% CI OR P 95% CI OR P 95% CI
Childhood cognitive score
 Bottom 10% Reference Reference Reference Reference
 Middle 80% 1.55 0.01 1.10, 2.19 1.66 0.07 0.96, 2.90 1.06 0.89 0.45, 2.48 1.26 0.84 0.14, 11.54
 Top 10% 1.06 0.79 0.68, 1.65 1.78 0.09 0.92, 3.44 1.28 0.60 0.50, 3.30 2.07 0.57 0.17, 25.65
Word learning test memory score at 69 years
 Bottom 10% Reference Reference Reference Reference
 Middle 80% 1.25 0.16 0.92, 1.70 1.27 0.28 0.82, 1.94 1.40 0.26 0.79, 2.49 1.15 0.86 0.25, 5.29
 Top 10% 1.56 0.07 0.97, 2.50 1.25 0.45 0.71, 2.21 1.77 0.13 0.85, 3.68 1.32 0.78 0.19, 8.94
Mental health prevalence at age 69
 No Reference Reference Reference Reference
 Yes 0.78 0.07 0.59, 1.02 0.91 0.60 0.63, 1.30 0.46 < 0.01 0.29, 0.73 0.28 0.01 0.10, 0.75
Lifetime smoking to 69 years
 Never smoker Reference Reference Reference Reference
 Ex‑smoker 0.98 0.86 0.81, 1.19 0.90 0.42 0.70, 1.16 0.99 0.97 0.73, 1.35 0.47 0.11 0.18, 1.18
 Current smoker 0.64 0.01 0.46, 0.88 0.70 0.14 0.43, 1.12 0.48 0.03 0.25, 0.94 0.33 0.21 0.06, 1.86
Alcohol use at age 69
 Never Reference Reference Reference Reference
 Less than once a week 1.09 0.58 0.80, 1.48 0.91 0.63 0.61, 1.35 1.28 0.34 0.77, 2.13 0.32 0.29 0.04, 2.62
 2–3× per week 1.21 0.25 0.87, 1.68 1.22 0.35 0.80, 1.85 1.91 0.02 1.13, 3.25 0.45 0.46 0.05, 3.73
 4+ times per week 1.17 0.35 0.84, 1.61 1.11 0.62 0.74, 1.67 1.29 0.33 0.77, 2.16 0.54 0.57 0.06, 4.63
Overweight at age 69
 No Reference Reference Reference Reference
 Overweight 0.74 0.01 0.58, 0.94 0.89 0.40 0.67, 1.17 1.61 0.01 1.14, 2.28 0.39 0.15 0.10, 1.43
 Obese 0.67 < 0.01 0.52, 0.86 0.95 0.72 0.70, 1.28 1.45 0.05 0.99, 2.12 0.17 0.01 0.05, 0.62
Type II diabetes at age 69
 No Reference Reference Reference Reference
 Yes 0.83 0.18 0.63, 1.09 1.04 0.85 0.70, 1.53 1.21 0.46 0.73, 2.01 0.68 0.50 0.22, 2.06
Hypertension by age 69
 No Reference Reference Reference Reference
 Yes 0.61 < 0.01 0.51, 0.73 0.86 0.21 0.69, 1.09 0.92 0.58 0.69, 1.23 0.98 0.94 0.46, 2.07
Overall disease burden at age 69
None Reference Reference Reference Reference
 1 0.81 0.13 0.62, 1.06 1.31 0.09 0.96, 1.78 0.79 0.24 0.54, 1.16 1.18 0.74 0.45, 3.12
 2 0.70 0.02 0.52, 0.94 1.01 0.94 0.71, 1.44 0.84 0.44 0.53, 1.31 1.15 0.81 0.36, 3.67
 3+ 0.72 0.03 0.53, 0.97 1.23 0.28 0.85, 1.77 0.63 0.04 0.40, 0.99 0.71 0.54 0.23, 2.15
Self‑rated health at age 68
 Poor Reference Reference Reference Reference
 Fair 1.05 0.85 0.62, 1.80 1.35 0.47 0.59, 3.08 1.40 0.61 0.39, 5.05 0.37 0.22 0.08, 1.81
 Good 1.30 0.31 0.78, 2.17 1.36 0.44 0.62, 2.97 2.66 0.12 0.77, 9.15 0.61 0.47 0.16, 2.35
 Very good 1.93 0.01 1.16, 3.22 1.65 0.21 0.76, 3.58 3.75 0.04 1.10, 12.77 0.91 0.88 0.25, 3.32
 Excellent 1.97 0.02 1.11, 3.50 2.07 0.09 0.89, 4.82 3.42 0.06 0.95, 12.29 1.00  ‑ 1.00, 1.00
APOE status
 No e4 Reference Reference Reference Reference
 e4 heterozygous 0.85 0.13 0.68, 1.05 0.99 0.97 0.75, 1.32 0.98 0.93 0.68, 1.42 1.08 0.88 0.41, 2.80
 e4 homozygous 1.27 0.39 0.73, 2.21 0.79 0.50 0.40, 1.56 0.97 0.95 0.38, 2.46 0.66 0.70 0.08, 5.46
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claustrophobia (n = 34) and metal implants (n = 28). 
Mean age at testing was 70.7 years (range 69.2 to 71.9), 
as expected for this age-homogenous group. Residen-
tial distance from the clinic ranged from 2 to 467 miles 
(mean = 112.6). Those who attended rated high visit sat-
isfaction (over 98%).
Higher educational attainment and non-manual SEP 
were predictors of attendance. The strongest predictor 
was a health self-rating of “very good” (OR = 4.39 (1.33, 
14.54)). Notably, greater distance from the clinic did not 
predict attendance (OR = 1.07 (0.71, 1.60)). We limited 
this analysis by comparing those who attended with those 
who refused; the pattern remained similar (Additional 
file 1: Table S2).
Those who had complete scans
Of the 502 who attended, 471 (94%) completed the PET/
MRI scan. Reasons for not completing were claustro-
phobia (n = 25); PET/MRI incompatibility issues (n = 4); 
recent illness (n = 1); withdrawal before being resched-
uled (n = 1; from n = 51 rescheduled scans). The direc-
tion of predictors of completion were mostly similar to 
previously observed; significant predictors were not 
having concurrent mental health problems (OR = 0.30) 
(0.11, 0.78) and not being obese (OR = 0.22) (0.07, 0.69) 
(Table 2).
Discussion
We provide a detailed overview of recruitment for an 
observational specialised (neuroscience) sub-study, 
embedded in the longest running British birth cohort, 
now in its early 7th decade. Participation requires a 
full day visit of intensive phenotyping and neuroimag-
ing, and in many cases considerable travel (mean travel 
distance = 112.55 miles) and overnight stay away from 
home (78%) [19]. Despite this, recruitment targets were 
met (original target n = 500, achieved target n = 502) and 
98% of those attended with high satisfaction.
However, even in a sample already biased towards 
higher SEP and education [8, 11], higher education and 
non-manual SEP in adulthood were independent and 
consistent predictors of recruitment at every stage; for 
example, from those who were invited, those from a 
non-manual adult SEP had 57% higher odds of attend-
ing the study compared to those from manual SEP 
(Table  2). Health-related characteristics, particularly 
higher cognition, were also predictive of every stage of 
recruitment, although these effects were largely attenu-
ated when adjusting for education and SEP. Reasons 
why lower childhood cognition, SEP and education are 
constant predictors of attrition may include reduced 
understanding or consideration of the importance of 
research, decreased confidence in participation, or con-
cerns about performance [8, 10].
Those who attended were less likely to be a current 
smoker, or to be obese; and had fewer clinical disor-
ders, better mental health, and “very good” or “excel-
lent” self-rated health. This may reflect those with 
healthier lifestyles and better health being more likely 
to be interested in health-related research, or may be 
more able to cope with the demands of travel and the 
assessments.
Notably however, sex and APOE-e4 genotype, an 
important predictor of β-amyloid load [20] and AD 
[21], were not predictors of participation at any level. 
The sex and APOE-e4 ratio are similar to national rates 
in England and Wales [22, 23].
The procedure and set-up of Insight 46 has simi-
lar demands to those of some preclinical AD trials; 
thus our results should prove useful in the design, 
SEP: socioeconomic position; OR: odds ratio. A: Comparing those that didn’t meet the specific life course data availability criteria vs those who did; B: comparing 
those that previously indicated they were not willing to attend a London-based clinic or didn’t respond vs those who were; C: comparing those that didn’t attend vs 
successfully attended; D: comparing those who were not scanned vs those successfully scanned
Italic values indicate p < 0.05
Table 2 (continued)
Variable A. Specific life course data 
available
B. Willingness for London-
clinic
C. Attended D. Scanned
OR P 95% CI OR P 95% CI OR P 95% CI OR P 95% CI
Residential distance to London centre (miles)
 < 60 Reference Reference Reference Reference
 60–120 0.99 0.92 0.79, 1.24 0.65 0.01 0.48, 0.90 1.21 0.09 0.96, 2.16 NA
 120–180 0.99 0.91 0.78, 1.24 0.40 < 0.01 0.29, 0.55 1.19 0.39 0.80, 1.78
 > 180 0.87 0.24 0.68, 1.10 0.36 < 0.01 0.26, 0.50 1.11 0.62 0.73, 1.68
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interpretation and generalisability of similar studies 
seeking to embed preclinical AD studies or trials. The 
rich sociodemographic and health-related behaviour 
measures collected prospectively over the life course in 
NSHD further allowed for a systematic assessment of 
predictors of participation.
In summary, we show that recruitment to and par-
ticipation in a neuroscience sub-study of a population-
based cohort is associated with bias towards higher 
SEP, education, cognitive function, and better health. 
Those at highest risk for negative outcomes may be 
under-represented in Insight 46. In many cases lon-
gitudinal studies such as this offer opportunities for 
assessing relationships between exposures and health 
outcomes across the life course, which may not require 
participants to be representative of the population at 
large [24, 25]. For studies that aim to be representative, 
associations with health-related outcomes may under-
estimate the strength of associations in the wider popu-
lation, which needs to be considered when interpreting 
results. Nevertheless, it is equally of interest to investi-
gate pre-clinical findings in a sample of lower risk.
Limitations
Our findings are based on a generation of British par-
ticipants in their early 7th decade, who are part of a 
lifelong study which may not directly generalise to 
younger populations, or populations outside of existing 
studies, where there may be less motivation to partici-
pate. In addition, our predictors of participation may 
be specific to single centre neuroimaging studies given 
that some people were only excluded due to unwilling-
ness to travel sometimes long distances. The data we 
describe have only related to cross-sectional recruit-
ment. We are currently undertaking longitudinal fol-
low-up of individuals which will enable investigation of 
predictors of study retention.
Additional file
Additional file 1: Table S1. Numbers and percentage of socioeconomic 
factors and health characteristics distribution for different stages of 
recruitment. Table S2. Analyses of socioeconomic and health characteris‑
tics predictors for those who were invited but refused attendance vs those 
who attended. Table S3. Original criteria of set of life course data available 
for Insight 46 eligibility.
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